Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 3/20 | 0.42 |
| ▸ | CTSS | P25774 | 3/20 | 0.38 |
| ▸ | CTSL | P07711 | 2/20 | 0.38 |
| ▸ | CTSB | P07858 | 2/20 | 0.38 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.37 |
| ▸ | KCNQ4 | P56696 | 3/20 | 0.36 |
| ▸ | KCNQ5 | Q9NR82 | 3/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.36 |
| ▸ | CTSK | P43235 | 1/20 | 0.36 |
| ▸ | CES2 | O00748 | 1/20 | 0.34 |
| ▸ | BCHE | P06276 | 1/20 | 0.34 |
| ▸ | CES1 | P23141 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.33 |
| ▸ | SYK | P43405 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4376494 | 0.86 | AKT1 (0.43) | AKT1CTSSCTSLCTSBKCNQ4 | |
| SCHEMBL15135380 | 0.84 | AKT1 (0.45) | AKT1CTSSCTSLCTSBKCNQ4 | |
| SCHEMBL23151026 | 0.79 | CES2 (0.40) | RIPK1CES2BCHECES1LMNA | |
| SCHEMBL4364528 | 0.78 | AKT1 (0.40) | AKT1CTSSCTSLCTSBRIPK1 | |
| SCHEMBL12060874 | 0.78 | AKT1 (0.48) | AKT1CTSSCTSLCTSBLMNA | |
| SCHEMBL15135360 | 0.74 | AKT1 (0.48) | AKT1CTSSCTSLCTSBKMT2A | |
| SCHEMBL15135598 | 0.73 | AKT1 (0.39) | AKT1CTSSCTSLCTSBKCNQ4 | |
| SCHEMBL13636272 | 0.73 | AKT1 (0.41) | AKT1CTSSCTSLCTSBCTSK | |
| SCHEMBL4371184 | 0.73 | AKT1 (0.50) | AKT1CTSSCTSLCTSBLMNA | |
| SCHEMBL20084192 | 0.73 | GCK (0.39) | AKT1SCN9ASYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1924563-B1 | 11-BETA-HYDROXYSTEROID DEHYDROGENASE-1-INHIBITOR-DIABETES-TYPE 2-1 | HOFFMANN LA ROCHE (CH) | 2013-07-31 | — | — | EP | disclosed |
| US-7622492-B2 | Pyrazolones as inhibitors of 11β-hydroxysteroid dehydrogenase | HOFFMANN-LA ROCHE INC. (US) | 2009-11-24 | — | — | US | disclosed |
| US-20070049632-A1 | Pyrazolones as inhibitors of 11B-hydroxysteroid dehydrogenase | BANNER BRUCE L | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049632-A1 | Pyrazolones as inhibitors of 11B-hydroxysteroid dehydrogenase | HSD17B1, HSD17B2, HSD3B2 | AKT1 1050/4885CTSS 3304/4885CTSL 4503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.